Vancouver, British Columbia – November 7th, 2024 – DiaGen AI Inc. is pleased to announce a partnership with Mila - Quebec Artificial Intelligence Institute.
Founded in 2021, DiaGen seeks to advance a diverse pipeline of artificial intelligence (AI) drug discovery solutions, focusing on protein and peptide design, vaccine development, and diagnostics for health wellness, longevity, and precision medicine.
By collaborating with Mila’s world-renowned network of experts and researchers in AI and machine learning, DiaGen’s team led by Dr. Eldad Haber and Mohit Pandey, will accelerate the design of bespoke therapeutic proteins to optimize key properties such as stability, synthesizability, and target binding, making an impact on human longevity and other critical areas of healthcare including cancer and immune disorders.
“This partnership between DiaGen and Mila provides a significant collaborative opportunity to increase our Canadian footprint into Quebec with the leading minds Mila has to offer to achieve impactful, AI driven discoveries and milestones much faster” said Paolo Lobo, President and COO at DiaGen.
“Mila is pleased to welcome DiaGen to its community of partners. By combining our expertise and research capabilities, this collaboration could offer new opportunities for DiaGen to advance its protein design, addressing unmet healthcare needs in Quebec and across Canada,” said Stéphane Létourneau, Executive Vice-President of Mila.
About Mila
Founded by Professor Yoshua Bengio of the University of Montreal, Mila is the world’s largest academic research center for deep learning, bringing together over 1,200 specialized researchers in machine learning. Based in Montreal and funded in part by the Government of Canada through the Pan-Canadian AI Strategy, Mila's mission is to be a global center for scientific advancements that inspire innovation and the growth of AI for the benefit of all. Mila is a globally recognized non-profit organization for its significant contributions to deep learning, especially in the fields of language modeling, automatic translation, object recognition, and generative models. For more information, visit mila.quebec.
About Diagen
Headquartered in Vancouver, DiaGen AI Inc is scaling a multi vertical and geographical diverse pipeline of projects and partnerships focusing on small molucule and peptide drug discovery, diagnsotics, and delivery using its proprietary AI engine DIA to de-risk, accelerate and create value disrupting traditional methods to advance precision medicine and impact global human longevity. For more information, visit www.diagen.ai.
To meet in person or virtually
Contact: Brian D. Keane, Chairman and CEO
Email: Brian@diagen.ai
